Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804465 · ClinicalTrials.gov registry record · Phase 2
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01804465 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT01804465, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects taking ipilimumab, as an immediate or delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and their prostate cancer.
Interventions
- DRUG Ipilimumab
- DRUG SipT Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-04-22 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804465
The ClinicalTrials.gov registry entry for NCT01804465 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01804465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01804465 about?
NCT01804465 is a clinical study titled "Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer". The purpose of this study is to find out what effects taking ipilimumab, as an immediate or delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and their prostate cancer.
What is the current status of trial NCT01804465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-04-22. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT01804465?
The interventions under investigation include: Ipilimumab (DRUG), SipT Treatment (DRUG).
Who is sponsoring clinical trial NCT01804465?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.